Get the Stockscreener App
10.18
2.86%
-0.30
After Hours:
10.22
0.04
+0.39%
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences - The Manila Times
When Will ARS Pharmaceuticals Reveal Its 2024 Financial Performance? - StockTitan
Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
ARS Pharmaceuticals' (SPRY) "Outperform" Rating Reaffirmed at William Blair - MarketBeat
Allspring Global Investments Holdings LLC Increases Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Earns Outperform Rating from William Blair - Defense World
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Allspring Global Investments Holdings LLC Has $3.63 Million Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Levi & Korsinsky Reminds Shareholders of an Investigation into ARS Pharmaceuticals, Inc. (SPRY) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Revolutionary Allergy Spray Gets Massive Insurance Breakthrough: Now Covered for Half of US Patients - StockTitan
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® ... - The Bakersfield Californian
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and - GlobeNewswire
Peregrine Capital Management LLC Invests $4.47 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals Presents Data On Neffy Epinephrine Nasal Spray At 2025 AAAAI Meeting - Nasdaq
ARS Pharmaceuticals to Showcase Innovation and Present Data - GlobeNewswire
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) ... - The Bakersfield Californian
Revolutionary Needle-Free Allergy Treatment Shows Superior Results: Clinical Data Reveals Game-Changing Efficacy - StockTitan
U.S. Inflation Readings Show Pick Up in Pricing Pressures - The Globe and Mail
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpHere's What Happened - MarketBeat
Oppenheimer Initiates Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - MarketBeat
(SPRY) Technical Data - Stock Traders Daily
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $615,500.00 in Stock - MarketBeat
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference - GlobeNewswire
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions - Seeking Alpha
Allergy Treatment Pioneer ARS Pharmaceuticals Takes Center Stage at Major Healthcare Conference - StockTitan
Ars Pharmaceuticals director Laura Shawver sells $615k in stock - MSN
Ars Pharmaceuticals director Laura Shawver sells $615k in stock By Investing.com - Investing.com Australia
ARS Pharma Rolls Dice Again On NeffyWill Persistence Pay Off? - RTTNews
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.3%What's Next? - MarketBeat
3 US Growth Stocks With Significant Insider Ownership - Simply Wall St
(SPRY) Investment Report - Stock Traders Daily
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.4% HigherStill a Buy? - MarketBeat
Allegations Against ARS Pharmaceuticals, Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Reach Out - ACCESS Newswire
ARS Being Investigated on Behalf of ARS Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Neffy Launches Free Epi Nasal Sprayer Program for U.S. Schools - Allergic Living
Equities Analysts Issue Forecasts for SPRY FY2025 Earnings - MarketBeat
What is William Blair's Estimate for SPRY FY2024 Earnings? - MarketBeat
William Blair Has Bullish Forecast for SPRY Q4 Earnings - MarketBeat
ARS Pharmaceuticals Launches neffyinSchools Program - GlobeNewswire
ARS Pharmaceuticals lays down 2025 objectives for epinephrine nasal spray - MSN
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lessened by ARS Investment Partners LLC - MarketBeat
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - The Manila Times
ARS Pharma Launches Free Neffy Nasal Spray Program for U.S. Schools to Combat Allergic Reactions - StockTitan
When (SPRY) Moves Investors should Listen - Stock Traders Daily
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $26.00 - MarketBeat
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):